Pathogenic role of human papillomavirus (HPV) DNA integration and clonal expansion in cervical tumorigenesis
Pathogenic role of human papillomavirus (HPV) DNA integration and clonal expansion in cervical tumorigenesis
批准号:
10537896
负责人:
EDWARD CHU
金额:
$20.96万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-06-01 至 2022-09-08
关键词:
AwardBar CodesBiological AssayCRISPR-mediated transcriptional activationCRISPR/Cas technologyCancer EtiologyCarcinomaCell Culture TechniquesCell CycleCellsCervicalCervical Intraepithelial NeoplasiaCervical dysplasiaCervix NeoplasmsCervix carcinomaCircular DNAClinicalClonal EvolutionClonal ExpansionClustered Regularly Interspaced Short Palindromic RepeatsCollectionColorContact InhibitionCustomDNADNA IntegrationDNA StructureDNA sequencingDevelopmentDiseaseDysplasiaEpisomeEpithelialEventFluorescent in Situ HybridizationFundingGenesGenomeGenomic DNAGenomic InstabilityGenomicsGoalsGrowthGuide RNAHPV-High RiskHistologicHumanHuman EngineeringHuman GenomeHuman PapillomavirusHuman papilloma virus 45Human papilloma virus infectionHuman papillomavirus 16Human papillomavirus 18IndividualInfectionInterphaseK-Series Research Career ProgramsKnowledgeLabelLaboratoriesLaboratory ResearchLentivirusLesionLocationMalignant NeoplasmsMalignant neoplasm of cervix uteriMapsMentorsMethodologyMethodsModelingMolecularMolecular StructureNormal CellNucleotidesOncogenesOncogenicOutcomePVT1 genePathogenicityPatientsPhasePhenotypePlasmidsPopulationPositioning AttributePropertyRecombinantsRecurrenceResearchResearch DesignResearch PersonnelResolutionRoleSamplingScienceScientistSequencing By HybridizationsSiteSurgeonSystemTechnologyTestingTimeTrainingTranscriptional ActivationTransfectionViralViral GenomeViral OncogeneWomanbasecareerds-DNAgenetic testinghuman DNAinsightintegration siteinterestkeratinocytelaboratory experiencemigrationnext generation sequencingnovelpremalignantprogramspromoterskillsspatiotemporaltooltranscriptomicstumortumorigenesistumorigenicviral DNA
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Summary/Abstract
Infection with high-risk Human Papillomavirus (hrHPV) is a necessary, key event in cervical
carcinoma. A major advance in understanding cervical cancer was the recognition that HPV DNA is integrated
into the human genome in almost all advanced cervical tumors. Human genome integration of HPV DNA 1)
stably associates the viral oncogenes with a host cell, 2) potentially drives expression of host oncogenes that
flank the sites of HPV DNA insertions, and 3) also causes human genome rearrangements. HPV integration is
thought to occur randomly in the human genome, but integrated HPV DNA in tumors is often inserted at one of
dozens of common genes in independent tumors, which suggests a clonal proliferation and survival advantage
of cells containing insertions at these positions. During the initial phase of my research laboratory training, I
developed an extensive, nascent research program to 1) detect and map HPV-human DNA junctions at single
nucleotide resolution (hybridization capture + next generation sequencing, HC+NGS), 2) thoroughly
characterize integrated viral DNA structure, and 3) describe the transcriptomic landscape in both cervical
dysplasia and carcinoma clinical samples. I also applied the HC+NGS assay to a recently developed cell
culture model where HPV circular DNA episomes replicate in early passage, human primary keratinocytes. I
found that HPV DNA integration occurs efficiently in this model, thus providing a potent system to study HPV
DNA integration and its functional consequences. To my knowledge, this is the first system for performing this
type of study. I detected HPV integrated into multiple sites in the human genome, some of which were detected
multiple times indicating clonal expansion of cells containing them. I hypothesize that HPV DNA integration is a
key molecular event that promotes clonal expansion of cells, and promotes the development of dysplasia and
invasive cervical carcinoma. In this application, I seek to develop my laboratory skills by generating and using
new tools to study the spatio-temporal consequences of HPV integration on clonal expansion in patient
derived, progressive cervical dysplasia lesions using multi-color, interphase DNA FISH assays (Aim 1); assess
tumorigenic properties of cultured keratinocytes (Aim 2) and finally to test the role of transcriptional activation
of flanking human genes in the expanded clonal populations (AIM 3). I will utilize a novel barcoding system
based on CRISPR activation of GFP in clones of interest combined with a custom recombinant HPV quasivirus
approach to lineage trace expanded HPV DNA integrated clones. I will carry out the proposed research over a
3 year period as part of the Early Surgeon Scientist Program Career Development Award. Along with my co-
mentors, Dr. Cristina Montagna and Dr. Jack Lenz, we have developed a training plan focusing on laboratory
science and methodology to achieve my career goal of becoming a fully independent and funded clinician
scientist.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
-
批准号:10494563
-
项目类别:
-
资助金额:$43.11万
-
财政年份:2021
-
负责人:EDWARD CHU
-
依托单位:
Training in Cancer Therapeutics Research
-
批准号:9150702
-
项目类别:
-
资助金额:$29.21万
-
财政年份:2015
-
负责人:EDWARD CHU
-
依托单位:
Training in Cancer Therapeutics Research
-
批准号:9331498
-
项目类别:
-
资助金额:$28.94万
-
财政年份:2015
-
负责人:EDWARD CHU
-
依托单位:
NCI ET-CTN with Phase i Emphasis at UPCI
-
批准号:9071388
-
项目类别:
-
资助金额:$97.34万
-
财政年份:2014
-
负责人:EDWARD CHU
-
依托单位:
NCI ET-CTN with Phase i Emphasis at UPCI
-
批准号:8725328
-
项目类别:
-
资助金额:$85.07万
-
财政年份:2014
-
负责人:EDWARD CHU
-
依托单位:
NCI ET-CTN with Phase i Emphasis at UPCI
-
批准号:8827308
-
项目类别:
-
资助金额:$57.04万
-
财政年份:2014
-
负责人:EDWARD CHU
-
依托单位:
Clinical Study of PHY906, a Novel Chinese Herbal Medicine, as a Modulator of Irin
-
批准号:9336547
-
项目类别:
-
资助金额:$34.74万
-
财政年份:2011
-
负责人:EDWARD CHU
-
依托单位:
Clinical Study of PHY906, a Novel Chinese Herbal Medicine, as a Modulator of Irin
-
批准号:8555270
-
项目类别:
-
资助金额:$51.14万
-
财政年份:2011
-
负责人:EDWARD CHU
-
依托单位:
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
-
批准号:7885768
-
项目类别:
-
资助金额:$74.99万
-
财政年份:2009
-
负责人:EDWARD CHU
-
依托单位:
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
-
批准号:7885774
-
项目类别:
-
资助金额:$69.96万
-
财政年份:2009
-
负责人:EDWARD CHU
-
依托单位:
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
-
批准号:8234199
-
项目类别:
-
资助金额:$25.56万
-
财政年份:2003
-
负责人:EDWARD CHU
-
依托单位:
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
-
批准号:8628948
-
项目类别:
-
资助金额:$25.41万
-
财政年份:2003
-
负责人:EDWARD CHU
-
依托单位:
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
-
批准号:8035468
-
项目类别:
-
资助金额:$25.56万
-
财政年份:2003
-
负责人:EDWARD CHU
-
依托单位:
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
-
批准号:7778299
-
项目类别:
-
资助金额:$17.73万
-
财政年份:2003
-
负责人:EDWARD CHU
-
依托单位:
Molecular Regulation of Translational Regulation
-
批准号:7187386
-
项目类别:
-
资助金额:$21.02万
-
财政年份:1999
-
负责人:EDWARD CHU
-
依托单位:
MOLECULAR BASIS FOR TRANSLATIONAL REGULATION
-
批准号:6174062
-
项目类别:
-
资助金额:$20.27万
-
财政年份:1999
-
负责人:EDWARD CHU
-
依托单位:
Molecular Regulation of Translational Regulation
-
批准号:7017019
-
项目类别:
-
资助金额:$21.65万
-
财政年份:1999
-
负责人:EDWARD CHU
-
依托单位:
MOLECULAR BASIS FOR TRANSLATIONAL REGULATION
-
批准号:2901915
-
项目类别:
-
资助金额:$17.41万
-
财政年份:1999
-
负责人:EDWARD CHU
-
依托单位:
MOLECULAR BASIS FOR TRANSLATIONAL REGULATION
-
批准号:6633505
-
项目类别:
-
资助金额:$22.15万
-
财政年份:1999
-
负责人:EDWARD CHU
-
依托单位:
MOLECULAR BASIS FOR TRANSLATIONAL REGULATION
-
批准号:6377449
-
项目类别:
-
资助金额:$20.88万
-
财政年份:1999
-
负责人:EDWARD CHU
-
依托单位:
海外基金